Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.01 and traded as low as $0.0002. Nascent Biotech shares last traded at $0.0043, with a volume of 5,157 shares trading hands.
Nascent Biotech Trading Up 48.3%
The company has a 50 day moving average of $0.01.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Stories
- Five stocks we like better than Nascent Biotech
- Stock Dividend Cuts Happen Are You Ready?
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is American Express the Credit Stock For a K-Shaped Economy?
- What is the S&P/TSX Index?
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
